Evolent Health (NYSE:EVH) Now Covered by Citigroup

Citigroup began coverage on shares of Evolent Health (NYSE:EVH) in a research report sent to investors on Monday, Marketbeat Ratings reports. The firm issued a buy rating and a $40.00 price target on the technology company’s stock.

Other equities analysts also recently issued reports about the company. JPMorgan Chase & Co. cut their target price on Evolent Health from $53.00 to $52.00 and set an overweight rating on the stock in a research report on Friday, March 15th. Oppenheimer started coverage on Evolent Health in a research report on Friday, March 1st. They issued an outperform rating and a $45.00 target price on the stock. Barclays started coverage on Evolent Health in a research report on Wednesday, January 3rd. They issued an overweight rating and a $39.00 target price on the stock. Canaccord Genuity Group cut their target price on Evolent Health from $45.00 to $44.00 and set a buy rating on the stock in a research report on Thursday, March 28th. Finally, JMP Securities increased their price target on Evolent Health from $37.00 to $38.00 and gave the stock a market outperform rating in a research report on Friday, February 23rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of Moderate Buy and an average target price of $42.70.

Evolent Health Stock Down 2.9 %

Evolent Health stock opened at $29.26 on Monday. The business has a fifty day moving average of $31.93 and a two-hundred day moving average of $30.29. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 0.56. The firm has a market cap of $3.38 billion, a P/E ratio of -23.04 and a beta of 1.53. Evolent Health has a twelve month low of $23.33 and a twelve month high of $36.70.

Evolent Health (NYSE:EVH) last posted its earnings results on Thursday, February 22nd. The technology company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.13. Evolent Health had a positive return on equity of 6.60% and a negative net margin of 5.76%. The company had revenue of $556.06 million during the quarter, compared to analyst estimates of $541.87 million. On average, analysts forecast that Evolent Health will post 0.87 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Evolent Health

Institutional investors have recently modified their holdings of the business. ICA Group Wealth Management LLC acquired a new stake in shares of Evolent Health during the 4th quarter valued at about $33,000. Signaturefd LLC grew its position in shares of Evolent Health by 1,470.7% during the 4th quarter. Signaturefd LLC now owns 1,445 shares of the technology company’s stock valued at $48,000 after acquiring an additional 1,353 shares during the period. NBC Securities Inc. purchased a new position in Evolent Health in the 4th quarter valued at about $69,000. Banque Cantonale Vaudoise purchased a new position in Evolent Health in the 1st quarter valued at about $88,000. Finally, Nisa Investment Advisors LLC lifted its stake in Evolent Health by 389.3% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,035 shares of the technology company’s stock valued at $137,000 after buying an additional 4,006 shares in the last quarter.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.